The drug, which targets specific exon mutations in a rare gastric cancer, showed strong preclinical results but wasn’t aligned with the larger company’s strategy, leading to its independent development, by a biotech startup.
Explore our news and updates as we deliver a superior customer experience.
News
02/17/2026
News
02/10/2026
News
12/19/2025